Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of Hepatocellular Carcinoma
Junwen Hu, Bin Chen, Jie Zhang, Yapeng Qi, Jiahao Liang, Jian‐Hong Zhong, Bang‐De Xiang
Abstract
Objective: To explore the effect of COX-2 inhibitor celecoxib in combination with metformin on the prevention of Hepatocellular carcinoma (HCC) and the mechanisms involved. Methods: HCC cell lines and an HCC rat model were treated with celecoxib, metformin or a combination of both. Cell viability and tumor formation were measured. Results: In vitro and in vivo studies showed that treatment with a combination of celecoxib and metformin inhibited proliferation of HCC to a greater extent than either treatment alone, by reducing the phosphorylation of MTOR.
Topics & Concepts
CelecoxibMetforminHepatocellular carcinomaMedicinePharmacologyIn vivoPI3K/AKT/mTOR pathwayCombination therapyCancer researchIn vitroInternal medicineApoptosisChemistryBiologyInsulinBiochemistryBiotechnologyInflammatory mediators and NSAID effectsCancer, Stress, Anesthesia, and Immune ResponseCancer, Lipids, and Metabolism